In myocardial infarction patients, in addition to dual anti-platelet therapy and the use of statins, a drug combination therapy of beta-blockers and ACE inhibitors or AT1 antagonists is established irrespective of the LVEF in order to improve cardiac perfusion and simultaneously avert ventricular remodeling [44]. The gene discussed is ACE; the disease is myocardial infarction.